US · Healthcare · Biotechnology
EPS came in at -1.14 against a street estimate of -1.23 — a beat of 7.3%.
Analysts rate Crinetics Pharmaceuticals Inc a strong buy (16 buy, 1 hold, 0 sell out of 17) with an average price target of $85.00.
| Fund | Stake |
|---|---|
| FMR Inc | 14.85% |
| BlackRock Inc | 7.99% |
| Farallon Capital Management, L.L.C. | 7.86% |
| Wellington Management Company LLP | 6.72% |
| Driehaus Capital Management LLC | 6.03% |
| T. Rowe Price Associates, Inc. | 5.05% |
| Vanguard Capital Management, LLC | 4.41% |
| Vanguard Portfolio Management, LLC | 4.37% |
| Document | Date |
|---|---|
| Acquisition completed · Q3 2026 CRINETICS PHARMACEUTICALS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Acquisition Price: $85.00 per share in cash • Total Deal Value: Approximately | 2026-09-01 |
| Shareholder vote results · Q3 2026 CRINETICS PHARMACEUTICALS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Merger Shareholder Vote Results (August 28, 2026): - Merger Proposal approve | 2026-08-28 |
| Company announcement · Q3 2026 CRINETICS PHARMACEUTICALS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Merger Consideration: $85.00 per share in cash for Crinetics common stock • To | 2026-08-19 |
| Company announcement · Q3 2026 CRINETICS PHARMACEUTICALS - FORM 8-K SUMMARY HEADLINE NUMBERS • Acquisition price/terms: Not specified in this document (refer to merger agreement f | 2026-08-14 |
| Quarterly report · Q2 2026 CRINETICS PHARMACEUTICALS, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Investments Position: $1.21 billion in cash, cash equivalents and i | 2026-08-03 |
| Quarterly report · Q1 2026 CRINETICS PHARMACEUTICALS, INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Assets: $1,401.3 million (March 31, 2026) vs. $1,126.3 million (Dec | 2026-05-07 |
| Proxy statement · Q2 2026 CRINETICS PHARMACEUTICALS PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of Three Class II Directors — Vote for thre | 2026-04-29 |
| Annual report FY2025 CRINETICS PHARMACEUTICALS, INC. — FORM 10-K SUMMARY HEADLINE NUMBERS • Company: Crinetics Pharmaceuticals, Inc., traded as CRNX on Nasdaq Global Sel | 2026-02-26 |
Readable in the app.
| Announcement | Date |
|---|---|
| Merger consummated; company delisted from Nasdaq following acquisition Crinetics Pharmaceuticals has been acquired and merged into a parent company for approximately $10 billion in total consideration. The merger was completed and became effective on the closin | 2026-09-01 |
| Shareholders approve merger with Vertex Pharmaceuticals Crinetics Pharmaceuticals shareholders voted to approve Vertex Pharmaceuticals' acquisition of the company on August 28, 2026. The merger agreement, dated July 6, 2026, will result in Crinet | 2026-08-28 |
| Merger with Vertex Pharmaceuticals; shareholder meeting scheduled for August 28 Crinetics Pharmaceuticals is being acquired by Vertex Pharmaceuticals in a merger agreement signed July 6, 2026. A shareholder vote is scheduled for August 28, 2026. However, three sharehold | 2026-08-19 |
| Merger with Vertex Pharmaceuticals receives antitrust clearances, closing expected September Vertex Pharmaceuticals is acquiring Crinetics Pharmaceuticals in a deal announced July 6, 2026. Key regulatory hurdles have been cleared: the U.S. HSR Act waiting period expired August 12, 2 | 2026-08-14 |
| Merger agreement announced; transaction subject to regulatory and stockholder approval This 8-K filing announces a merger transaction between the company and a parent company, with the document primarily consisting of forward-looking statements disclaimers and risk disclosures | 2026-07-10 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Crinetics Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.